Key statistics
On Friday, Syndax Pharmaceuticals Inc (1T3:DUS) closed at 17.30, -9.42% below its 52-week high of 19.10, set on Dec 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 16.70 |
|---|---|
| High | 17.30 |
| Low | 16.70 |
| Bid | 17.60 |
| Offer | 18.00 |
| Previous close | 16.90 |
| Average volume | 220.00 |
|---|---|
| Shares outstanding | 86.91m |
| Free float | 85.80m |
| P/E (TTM) | -- |
| Market cap | 1.75bn USD |
| EPS (TTM) | -3.61 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Announcements
- Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
- Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
- Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
- Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
- Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
More ▼
